LPCN compared with ZNTL: revenue, margins and what each company keeps, and the suppliers and customers both name

LPCNLipocine Inc.

Mkt capRevenueRevenue

ZNTLZentalis Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

LPCNLipocine Inc.

ZNTLZentalis Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LPCN1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.95%—

ZNTL1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.3%▼−15.60%×1.09

= impliedLPCN realized, solidZNTL realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data

LPCNLipocine Inc.

1.43▼−0.69%

Mkt cap$11.9MRevenue$190,099Q2 FY26Revenue$2MFY25

ZNTLZentalis Pharmaceuticals, Inc.

1.85▼−5.58%· post 1.75

ClosedNov 2 '26

Mkt cap$132.6MRevenue$27MQ4 FY24Revenue—

Compare

ClosedNov 2 '26

LPCNLipocine Inc.

ZNTLZentalis Pharmaceuticals, Inc.

1.43▼−0.69%

Price

1.85▼−5.58%post 1.75

$11.9M

Mkt cap

$132.6M

Q2 FY26$190,099

Revenue

$27MQ4 FY24

FY25$2M

Revenue

—

LPCN1.43▼−0.69%vsZNTL1.85▼−5.58%ClosedNov 2 '26